Navigation Links
India continues to progress in AIDS vaccine development efforts
Date:8/16/2008

Chennai, August 16, 2008 A second Phase I AIDS vaccine clinical trial in India was successfully completed, the Indian Council of Medical Research, the National AIDS Control Organization and the International AIDS Vaccine Initiative announced. The results of the trial of an MVA-based AIDS vaccine candidate (TBC-M4), which was conducted in Chennai, indicated that the vaccine candidate had acceptable levels of safety and was well tolerated.

The proportion of volunteers whose immune systems responded to the vaccine candidate suggests the candidate holds promise. The trial was done using two doses of the candidate vaccine. After three injections, 82 percent of the volunteers who received a low dose and 100 percent of those who received a high dose registered immune responses to the vaccine. The 100 percent response rate is greater than that seen with the majority of AIDS vaccine candidates tested in humans to date. However the strength and diversity of these immune responses were modest. It may be possible to boost the immune response, if this vaccine is used in combination with other candidate AIDS vaccines.

"We are pleased to see that the MVA-based candidate tested in Chennai was safe and showed promising initial immune responses. We do not know whether these observed responses will ultimately translate into an effective vaccine that will help protect individuals from HIV infection, but hope to learn more through further testing," said Dr. S K Bhattacharya, Additional Director General of the Indian Council of Medical Research. "India is playing a significant role in global AIDS vaccine discovery efforts given our strong medical and scientific capabilities. There is a need for continued efforts for the creation of novel, reliable mechanisms for long-term research on AIDS vaccines and other new prevention technologies."

The Phase I clinical trial was initiated in January 2006 at the Tuberculosis Research Center (TRC), an Indian Council of Medical Research (ICMR) institute in Chennai, and was completed in February 2008. This trial was conducted under the aegis of a Memorandum of Understanding (MoU) between the Government of Indiathrough the Indian Council of Medical Research (ICMR) and the National AIDS Control Organization (NACO)and the not-for-profit International AIDS Vaccine Initiative (IAVI). YRG CARE, based in Chennai, collaborated with TRC to mobilize the community around the Phase I trial.

Dr. Narayanan, former Director of the Tuberculosis Research Center, added, "Consistent innovation in science despite setbacks has ensured the development of many effective prevention technologies. The successful conduct of the trial in Chennai re-affirms the need for continued vaccine development initiatives, where learnings from every effort will contribute to global advancement of the AIDS vaccine field."

About the Phase I MVA-based (TBC-M4) AIDS vaccine trial

The trial was a double blind, dose-escalation, randomized, placebo-controlled trial, which was initiated after receiving all necessary regulatory and ethical clearances. The objectives of such a Phase I trial are to evaluate the safety of the vaccine candidate and to gather preliminary results of immune responses induced by the candidate. The total duration of the trial was approximately 24 months. The volunteers recruited for this trial were 32 healthy, HIV-uninfected men and women between 18 and 50 years of age, from all socio-economic strata. Three intra-muscular injections of TBC-M4 or placebo were administered to the volunteers.

Moving forward

The results of the Phase I vaccine trial of TBC-M4 suggest that further research is warranted. Currently, two additional Phase I trials testing the MVA-based candidate in a prime-boost regime are planned and under review by the relevant authorities in India and approved in the UK. The trials are designed to use different modes of administration of the priming vaccine, different dosages and different vaccine regimens. It is hoped that the prime-boost regimen will help to strengthen the modest immune responses observed in the Phase I trial of the MVA-based candidate alone. Collectively, the results will help determine whether and how to move forward with additional testing of this MVA-based AIDS vaccine candidate.

Simultaneously, IAVI has undertaken work to modify the MVA-based vaccine candidate so that it is ready for large-scale manufacturing should the trial results suggest further testing is warranted.


'/>"/>

Contact: Lisa Beyer
lbeyer@iavi.org
917-239-3858
International AIDS Vaccine Initiative
Source:Eurekalert

Related medicine news :

1. Rohm and Haas Expands in India
2. Income inequality associated with overnourishment and undernourishment in India
3. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
4. WellPoint and M-Plan Enter Into Endorsement Agreement as M-Plan Announces Exit From the Commercial HMO Business in Indiana
5. Global Health Project targets reducing AIDS among Indias adolescents
6. EPA: Nine Indiana Counties Now Meet the Health Standard for Smog
7. US-Based Bollywood On-Demand Service to Sponsor Faces of India YouthAIDS Gala on November 2nd
8. India, UK Join Growing List of Countries to Require Pictorial Tobacco Warnings
9. National Geographic Channel, Ashley Judd and YouthAIDS Host World Premiere Screening of Indias Hidden Plague
10. EmPower Research Launches Indian CRO Industry Report
11. Indiana Attorney General Steve Carter Addresses Drunk Driving and Underage Drinking in New Radio Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... 2016 , ... Derrin Doty Group has unveiled the latest charity campaign in ... west of Seattle. The insurance provider’s caring team has been so moved by the ... to complications from the flu, that they have decided to extend their original campaign. ...
(Date:5/5/2016)... Portland, Oregon (PRWEB) , ... May 05, 2016 ... ... the Student American Chiropractic Association (SACA) is slated to host the 2016 National ... chance for all current SACA national officers and chapter officers to come together ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... Vitenas Cosmetic ... Healthcare Design Awards, presented by the American Institute of Architects and the Academy of ... by the renowned Perkins+Will and Harrell Architects, opened to patients in October of 2014. ...
(Date:5/5/2016)... ... May 05, 2016 , ... Dr. Benjamin Stong of Kalos Facial ... treatment. Dr. Stong is double board certified and the only facial plastic surgeon ... of hair loss. Non-surgical therapies such as stem cells can be used to provide ...
(Date:5/5/2016)... ... ... In honor of National Nurses Week 2016, Aya Healthcare , the ... thank a nurse who's made a difference in their life. From Friday, May 6 ... of San Diego/Imperial Counties (up to $10,000) every time someone tells them via social ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... an upgrade. There are many medical recorders on the market but none like this. ... HD  offers unparalleled connectivity and functionality.  Ampronix  is a renowned authorized reseller of the ... Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
(Date:5/4/2016)... New Jersey , May 4, 2016 ... its successful completion of an alternative public offering (APO). ... wholly owned operating company, Valeritas, Inc. and a private ... common stock at $5.00 per share. Under ... on May 3, 2016, Valeritas Holdings, Inc. will trade ...
(Date:5/4/2016)... 2016 Research and ... Acute lymphocytic Leukemia Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Market and Competitive Landscape Highlights 2016, provides ... products, Acute Lymphocytic Leukemia epidemiology, Acute Lymphocytic ...
Breaking Medicine Technology: